Follicular Lymphoma: Forecasting Bispecific Antibody Treatment Strategies
Closing out their discussion on bispecific antibody therapies, Matthew Matasar, MD and Laurie Sehn, MD, consider ongoing clinical trials and real-world use of these novel agents.
Bispecific Antibodies in Relapsed/Refractory Follicular Lymphoma: AE Management
Experts Matthew Matasar, MD and Laurie Sehn, MD, nuance the adverse event profiles of bispecific antibody therapies and consider how these will help inform treatment decisionmaking.
Advent of Bispecific Antibodies for Relapsed/Refractory Follicular Lymphoma
Expert perspectives on the advent of bispecific antibody therapy in relapsed/refractory follicular lymphoma, centered on data and experience with several novel agents.
Multiply Relapsed Follicular Lymphoma: Overview on CAR T-Cell Therapy
Shared insight on the development and use of CAR T-cell therapy in patients with multiply relapsed follicular lymphoma.
Novel Targeted Agents in Multiply Relapsed Follicular Lymphoma
Switching to the paradigm of multiply relapsed follicular lymphoma, expert participants discuss the rationale behind and use of PI3k- and EZH2- targeted therapies.
Relapsed/Refractory Follicular Lymphoma: Second-Line Treatment Armamentarium
Matthew Matasar, MD and Laurie Sehn, MD, share insight on available therapies for relapsed or refractory follicular lymphoma and reflect on factors that help in treatment selection.
First-Line Treatment Strategies in Follicular Lymphoma
Centering discussion on both symptomatic and asymptomatic disease, expert participants highlight cornerstone frontline therapies in follicular lymphoma.
Follicular Lymphoma Workup: What is the Role of PET Imaging?
A brief review of the role that PET imaging plays in staging follicular lymphoma and how it may inform treatment decisions.
Follicular Lymphoma Workup: Risk Stratification and Staging
Key opinion leaders in the management of follicular lymphoma share their perspective on risk stratification and staging strategies to inform treatment decisionmaking.
An Overview on the Nature of Follicular Lymphoma
Opening their discussion on follicular lymphoma, experts Matthew Matasar, MD and Laurie Sehn, MD, reflect on its indolent nature as a subset of non-Hodgkin lymphoma.
Loncastuximab Shows Durable Response in Higher-Risk R/R DLBCL Population
Matthew J. Matasar, MD, discusses the LOTIS-2 trial of loncastuximab tesirine in patients with relapsed/refractory diffuse large B-cell lymphoma.
Changes in the Treatment Landscape for Patients With DLBCL
Matthew J. Matasar, MD, discusses the current landscape of diffuse large B-cell lymphoma.
New Treatment Regimen Examined in POLARIX Trial for Patients With DLBCL
Matthew J. Matasar, MD, discusses how updates in the diffuse large B-cell lymphoma field have led to improved quality of life in patients.
Matasar Considers Treatment Options in B-Cell Lymphoma
Matt Matasar, MD, discusses treatment options in B-cell lymphomas.
2 Clarke Drive Cranbury, NJ 08512